The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer by Bruno, A. et al.
Volume 15 Number 2 February 2013 pp. 133–142 133Abbreviati
Address all
Modelli A
1This wor
Ministero
Ateneo de
Progetto S
Cellular an
The autho
2This artic
3These au
Received 1
Copyright
DOI 10.1
www.neoplasia.comThe Proangiogenic Phenotype
of Natural Killer Cells in
Patients with Non–Small
Cell Lung Cancer1,2ons: NSCLC, non–small cell lung cancer; SCC, squamous cell carcinoma; Ad
correspondence to: Dr Adriana Albini, Director, Research and Statistics Infrastruc
ssistenziali in Oncologia”, Arcispedale S. Maria Nuova, Viale Umberto I, 50, 42
k was supported by grants from the Associazione Italiana per la Ricerca sul C
Italiano della Salute, Programma Strategico Ricerca Oncologica to G.F. and A.A
lla Ricerca (FAR) to D.M.N. and L.M.), and MultiMedica Onlus (to A.A.). C
trategico” fellow; A.B. was supported by the University of Insubria Cellular and
d Molecular Biology Doctoral program of the University of Insubria. A.B. and
rs declare no conflict of interest.
le refers to supplementary materials, which are designated by Table W1 and
thors contributed equally.
8 October 2012; Revised 5 November 2012; Accepted 10 December 2012
© 2013 Neoplasia Press, Inc. All rights reserved 1522-8002/13/$25.00
593/neo.121758Antonino Bruno*,3, Chiara Focaccetti†,3,
Arianna Pagani‡, Andrea S. Imperatori§,¶,
Marco Spagnoletti§,¶, Nicola Rotolo§,¶,
Anna Rita Cantelmo*, Francesca Franzi§,
Carlo Capella§, Guido Ferlazzo#,
Lorenzo Mortara‡, Adriana Albini†,3
and Douglas M. Noonan*,‡,3
*Scientific and Technology Park, IRCCS MultiMedica,
Milan, Italy; †Department of Research and Statistics
Infrastructure, IRCCS Arcispedale Santa Maria Nuova,
Reggio Emilia, Italy; ‡Department of Biotechnology and
Life Sciences, University of Insubria, Varese, Italy;
§Department of Surgical and Morphological Sciences,
University of Insubria, Varese, Italy; ¶Center for Thoracic
Surgery, University of Insubria, Varese, Italy; #Department
of Human Pathology, University of Messina, Messina, ItalyAbstract
The tumor microenvironment can polarize innate immune cells to a proangiogenic phenotype. Decidual natural killer
(dNK) cells show an angiogenic phenotype, yet the role for NK innate lymphoid cells in tumor angiogenesis remains
to be defined. We investigated NK cells from patients with surgically resected non–small cell lung cancer (NSCLC)
and controls using flow cytometric and functional analyses. The CD56+CD16− NK subset in NSCLC patients, which re-
presents the predominant NK subset in tumors and a minor subset in adjacent lung and peripheral blood, was associated
with vascular endothelial growth factor (VEGF), placental growth factor (PIGF), and interleukin-8 (IL-8)/CXCL8 production.
Peripheral blood CD56+CD16− NK cells from patients with the squamous cell carcinoma (SCC) subtype showed higher
VEGF and PlGF production compared to those from patients with adenocarcinoma (AdC) and controls. Higher IL-8 produc-
tion was found for both SCC and AdC compared to controls. Supernatants derived from NSCLC CD56+CD16− NK cells
induced endothelial cell chemotaxis and formation of capillary-like structures in vitro, particularly evident in SCC patients
and absent from controls. Finally, exposure to transforming growth factor–β1 (TGFβ1), a cytokine associated with dNK
polarization, upregulated VEGF and PlGF in peripheral blood CD56+CD16− NK cells from healthy subjects. Our data
suggest that NK cells in NSCLC act as proangiogenic cells, particularly evident for SCC and in part mediated by TGFβ1.
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Lung cancer is the predominant cause of cancer-related mortality in the
developed world and is the leading cause of death from cancer in man.
Approximately 80% of all lung cancers are non–small cell lung cancer
(NSCLC) that can be divided phenotypically into two principal subtypes,
squamous cell carcinoma (SCC) and adenocarcinoma (AdC). Although
often treated similarly in therapy, they differ not only pathologically and
functionally but also in their response to targeted therapeutic agents.
Experimental and expanding clinical evidence indicates that while
immune cells can contribute to tumor rejection [1], they often play a
key role in initiating and promoting cancer [2,3]. These opposing
functions are in large part due to polarization of immune cells within
tumors as well as to immune cell editing, modulation of tumor micro-
environment, and immunosuppression [1–3]. This concept of polari-
zation resulting in attenuation of antitumor activity and enhancement
of processes favoring tumor growth, including angiogenesis, is well
established for macrophages [4,5]. Similar phenomena have been ob-
served for most immune cells depending on the model system, includ-
ing neutrophils and T and B cells [2,3]. However, relatively little is
known concerning the effects of tumor and tumor microenvironment–
derived factors on natural killer (NK) cell polarization.
NK cells are the major subset of innate lymphoid cells endowed
with complex regulatory roles [6] originally identified as innate im-
mune cells able to recognize and kill cells lacking—or with very low
expression of—class I major histocompatibility complex molecules
[7]. Additional analyses have identified multiple subsets of NK cells
and the complexity of NK cells is increasingly appreciated [7,8]. There
are two main NK cell subsets. The major subset, approximately 95% of
circulating NK cells in peripheral blood, is characterized as being
CD56dimCD16+, have strong production of granzyme and perforin,
and are generally associated with cytotoxicity. The remaining approxi-
mately 5% of circulating NK cells are CD56brightCD16− and show
lower cytotoxicity and higher levels of cytokine production [7,8]. Re-
markably, within the developing decidua, there is another very different
NK cell subset [decidual NK (dNK) cells] that displays a cytokine-
secreting, highly angiogenic phenotype [9–11] in humans and mice.
Human dNK cells are CD56superbrightCD16−, produce vascular endo-
thelial growth factor (VEGF), placental growth factor (PIGF), and
interleukin-8 (IL-8), and can significantly enhance growth of trans-
planted tumors by their angiogenic activity [9].
NK cells play an important role in tumor immune control and in the
modulation of adaptive antitumor T cell immunity, as well as in the
cooperation with dendritic cells, for example, by secretion of interferon-γ
(IFN-γ) and tumor necrosis factor α (TNFα) [12,13]. The majority of
studies on human NK cell biology have been performed on peripheral
blood NK cells rather than on those infiltrating tissues. Lung tissues are
particularly rich in NK cells [14,15] possibly because of spontaneous
IL-15 production by bronchial epithelial cells [16]. Human NSCLCs
are infiltrated by the predominant subset of CD56brightCD16−NK cells
[17,18] that appear to be selectively recruited into tumors, showing
substantial cytokine production, expressing killer inhibitory receptors
[17,18] yet have a reduced killing capacity [17].
Given the strong proangiogenic activity of dNK cells and the consis-
tent activation of angiogenic programs in immune cells by tumors, here
we show angiogenic cytokine production and angiogenesis-associated
activities by NK cells from NSCLC cancer, particularly evident in
NK cells from patients with SCC.
Transforming growth factor–β (TGFβ), an immunosuppressive
cytokine [19] with a pleiotropic role in tumor biology [20], is a cyto-kine frequently overexpressed in many cancers [20] including NSCLC
[21]. TGFβ also has a role in the tumor microenvironment immune
cell polarization [19], including macrophages, neutrophils, and NK
cells, associated with tumor immune evasion [19]. High expression
of TGFβ is characteristic of NSCLC and predictive of poor survival
for patients with the SCC subtype [22]. The development and differ-
entiation of human NK cell subsets in vitro is known to be effected by
TGFβ and has been previously suggested to induce a polarization of
peripheral blood NK cells toward a dNK-like CD56superbrightCD16−
phenotype [23,24]. In vitro exposure of peripheral blood NK cells from
healthy donors to TGFβ1 upregulated production of angiogenic cyto-
kines, suggesting a role for this cytokine in inducing a proangiogenic
NK phenotype.Patients, Materials, and Methods
Patient Selection and Samples
Samples (tumor tissue and macroscopically normal adjacent tissues)
from 31 patients with NSCLC were obtained during surgical resections
after obtaining informed consent in an institutional ethics committee–
approved study. The patient population characteristics are shown in
Table W1. Tissue samples were placed in phosphate-buffered saline
(PBS; LONZA, Basel, Switzerland) with 1% Pen/Strep (Sigma-
Aldrich, St Louis, MO) at 4°C for no more than 18 hours before pro-
cessing. Peripheral blood samples were drawn from the same patients
before surgical intervention into blood collection heparinized tubes,
stored at 4°C, and processed within 18 hours. Patients with diabetes, hu-
man immunodeficiency virus (HIV)/hepatitis C virus (HCV)/hepatitis B
virus (HBV) infection, overt chronic inflammatory conditions, previ-
ously treated with chemotherapy or radiotherapy, or those iatrogenically
immunosuppressed or having undergone myeloablative therapies were
excluded. As controls, adjacent normal lung samples were obtained from
patients who underwent minimal lung resection for bullectomy to
treat pneumothorax following informed consent and processed as
above (Table W1). Peripheral blood samples were obtained from
healthy donors.
Patient Characteristics
NK cells were isolated from blood, lung tumor, and adjacent healthy
tissues from 31 NSCLC patients having undergone tumor resection
(median age, 71; range, 44–79), as well as blood and macroscopically
normal lung tissue from 10 patients having undergone minimal lung
resection for bullectomy (median age, 27; range, 16–69), whose char-
acteristics are shown in Tables 1 and W1. Consistent with the popu-
lation at risk, the majority of the cancer patients were males (90%) and
either former or current smokers (90%). The most frequent subtype
was AdC (17; 55%), followed by SCC (9; 29%) and tumors of other
subtypes. Lung tissue controls were predominantly male (90%) and
current or former smokers (70%; Table W1).
Isolation of Peripheral Blood Mononuclear Cells
To obtain peripheral blood mononuclear cells, a density gradient
was performed on heparinized peripheral blood by diluting the sam-
ple 1:1 with RPMI 1640 (LONZA). This suspension was then care-
fully stratified on Lymphocyte Separation Medium (LONZA) and
centrifuged at 500g for 30 minutes at room temperature with no brake.
The lymphocyte-containing ring at the interface was collected in a new
tube and washed twice in PBS by centrifugation.
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The solid tissues obtained (tumor, adjacent normal, and non-
oncologic lung tissues) were extensively washed in PBS to remove
cell debris and eventual red blood cell aggregates and mechanically
minced by scissors to obtain small fragments that were enzymatically
digested with a cocktail containing DNAse (100 μg/ml; Roche,
Mannhein, Germany) and Collagenase (1 mg/ml; Sigma-Aldrich)
in RPMI 1640 supplemented with Pen/Strep for 1 hour at 37°C. The
suspension was then filtered on cell strainers [Becton Dickinson (BD),
San Jose, CA], while the remaining tissue fragments were processed in
a tissue dissociator (gentleMACS; Miltenyi Biotec, Auburn, CA) and
subsequently filtered as above. The total single cell suspension was
washed by centrifugation in PBS to remove residual enzymes.
Phenotypic Characterization of Tumor Infiltrating NK Cells
Cells from blood, tumor, and normal adjacent tissue (3 × 105 cells
per sample) were stained with the following monoclonal antibodies
(mAbs) in a direct immunofluorescence assay and assessed by flow
cytometry (FACS Canto I; BD): Leucogate [BD; fluorescein isothio-
cyanate (FITC)–conjugated anti-human CD45 and phycoerythrin-
conjugated (PE) anti-human CD14] was used to gate on lymphocytes.
FITC-conjugated anti-human CD16 (BD, clone 3G8), peridinin-
chlorophyll-protein complex (PerCP)–conjugated anti-human CD3
(Miltenyi Biotec, clone BW264/56), and allophycocyanin (APC)–
conjugated anti-human CD56 (Miltenyi Biotec, clone AF12-7H3) were
used to detect NK cells. Negative controls included directly labeled
FITC-conjugated, PerCP-conjugated, and APC-conjugated isotype-matched irrelevant mAbs (BD). Briefly, after physical parameter setting
(Forward and Side Scatter), lymphocyte populations were identified by
gating onCD45-positive cells, and then theNK cell subpopulations were
distinguished by gating on CD3-negative cells/CD56-positive cells using
the isotypic controls. The CD3−CD56+ NK population was evaluated
for CD16 expression.
Cytokine and Angiogenic Growth Factor Expression by
NK Cells
The total cell suspensions were incubated overnight in RPMI 1640
supplemented with heat-inactivated FBS (Euroclone, Milan, Italy),
Pen/Strep, and IL-2 (100 U/ml; R&D Systems, Minneapolis, MN) at
37°C and 5% CO2. Cells (3 × 10
5/ml) were then stimulated for 6 hours
with 10 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich,
St Louis, MO), 500 ng/ml ionomycin (Sigma-Aldrich), and protein
transport inhibitor Brefeldin-A (Golgi Plug, BD) and then treated with
Cytofix/Cytoperm fixation and permeabilization kit (BD). The expres-
sion of specific cytokines and angiogenic growth factors by NK subpo-
pulations were evaluated by flow cytometric analyses after staining with
anti-human Leucogate and phenotype detection markers (CD16-FITC/
CD3-PerCP/CD56-APC) combined with PE-conjugated anti-human
VEGF (R&D Systems; clone 23410), PE-conjugated anti-human IL-8
(R&D Systems; clone 6217), and PE-conjugated anti-human IFN-γ
(BD; clone 25723.11). Negative controls included directly
labeled isotype-matched irrelevant mAbs (BD). For PlGF staining, an
unconjugated mAb was used (R&D Systems; clone 37203.111)
coupled with a secondary PE-conjugated mAb goat anti-mouse IgG1Table 1. Characteristics of All Patients with Resected NSCLCs Analyzed.Patient No. Gender Age (Years) Histology T N M Stage* Smoking Status Tumor Infiltrating NK Lung Tissue Infiltrating NK Peripheral Blood NKPercentage of
Total CD45+,†Percentage of
CD16− NK‡Percentage of
Total CD45+,†Percentage of
CD16− NK‡Percentage of
Total CD45+,†Percentage of
CD16− NK‡1 M 77 AdC 4 0 0 IIIA Former 1.4 77.7 0.7 1 9.9 2.8
2 M 70 AdC 1a 0 0 IA Former 0.4 83 0.1 40.5 15 2.3
3 M 77 AdC 2a 0 0 IB Former 1.6 69.3 0.8 13.2 35.9 3.9
4 M 54 AdC 2a 0 0 IB Former 1.2 74.8 0.7 16.1 20.9 2
5 M 60 NLC 1b 2 0 IIIA Current 0.2 59.1 2 18.4 12.9 10.3
6 M 75 AdC 3 1 0 IIIA Former 23.3 83.3 0.2 32.1 21.3 3.2
7 M 67 AdC 2b 0 0 IIA Former 1.7 64.9 7.5 13.9 0.5 28.4
8 M 71 St 3 1 0 IIIA Former 7.5 72.4 0.7 21 36.8 1.1
9 M 59 SCC 1a 0 0 IA Current 0.2 52.1 0.9 19.8 3.3 10.2
10 M 73 AdC 2a 0 0 IB Current 1.9 87.3 0.3 21.4 0.6 13.5
11 M 56 AdC 2a 0 0 IB Current 0.3 55.9 0.2 38.5 30.7 1.6
12 F 72 LCC 3 0 0 IIB Current 0.8 75 6.9 27.4 0.2 43.3
13 M 78 SCC 1a 0 0 IA Former 0.6 64 8.8 18 1.4 22.6
14 M 70 AdC 1a 0 0 IA Current 5.5 55.5 0.8 19.7 0.6 9.7
15 M 67 AdC 2a 0 0 IB Current 2.4 56.9 0.2 47.3 2 33.3
16 M 73 AdC 2a 0 0 IB Former 0.2 88.5 1.1 14.3 5.2 33.3
17 M 56 LCC 2a 1 0 IIA Current 0.1 87.5 1.7 14.4 0.1 22.7
18 M 67 SCC 2b 0 0 IIA Current 0.9 98.3 3.1 21.1 7.9 7.6
19 M 79 AdC 2a 0 0 IB Former 0.6 89.9 0.7 0.3 0.1 43.3
20 M 52 AdC 1b 1 0 IIA Never 3.3 96.1 0.9 4.1 0.7 1.4
21 M 73 SCC 2a 0 0 IB Former 1.6 72.7 0.1 25 0.8 25
22 M 66 SCC 1b 0 0 IA Former 0.1 92.4 0.6 6.3 2 17.4
23 M 73 SCC 1b 2 0 IIIA Former 2.9 73 2 8.3 0.3 23.7
24 M 66 SCC 1b 0 0 IA Former 1.3 89.9 0.8 20.8 0.8 19
25 M 72 SCC 2 2 0 IIIA Current ND ND ND ND 12.3 ND
26 M 74 SCC 3 0 0 IIB Former ND ND ND ND 0.1 ND
27 M 71 AdC 2 1 0 IIB Current ND ND ND ND 0.1 ND
28 M 63 AdC 1b 1 0 IA Current ND ND 0.4 ND 1.4 ND
29 F 74 AdC 1b 0 0 IA Never 1 ND 0.3 ND 0.1 ND
30 M 73 AdC 2a 0 0 IB Former 0.2 ND 2.3 ND 0.3 ND
31 F 72 SCC 1 0 0 IA Never 0.4 ND 0.3 ND 13 NDAdC indicates lung adenocarcinoma; SCC, squamous cell lung carcinoma; NLC, neuroendocrine large cell lung carcinoma; LCC, large cell lung carcinoma; St, sarcomatoid lung cancer; ND,
not determined.
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a negative control.
Immunohistochemistry of Tumor Samples
A portion of each tumor sample was retained fixed in formalin and
embedded in paraffin for routine histopathology. Sections were
stained for CD31 (Dako, Glostrup, Denmark; clone JC/70A) as a
marker for vessels, CD57 (clone HNK-1; R&D Systems) as a marker
for activated NK cells, and CD56 (Dako; clone T199) and CD3
(Ventana, Tucson, AZ; clone 2GV6) as markers for NK cells. Serial
sections showing cells staining with CD56 but not CD3 and with
appropriate morphology were considered to be NK cells.
NK Cell Enrichment
Total NK cells derived from blood or tissue samples were enriched
with an immunomagnetic negative NK cell selection kit (MagCellect
Human Kit; R&D Systems) from the cell suspensions obtained as
above from blood, tumor, and adjacent lung tissue. Briefly, cells
were resuspended into MagCellect buffer, and negative selection was
performed by incubating for 15 minutes with MagCellect NK cell
biotinylated antibody cocktail and for 15 minutes with MagCellect
streptavidin ferrofluid reagent and then placed in a magnetic field that
retains the unwanted fraction. NK enrichment greater than 85% was
confirmed using flow cytometry assays.
Chemotaxis and Morphogenesis of Human Umbilical Vein
Endothelial Cells
NK cells purified from blood and tissues were incubated overnight
as previously described. Cells were incubated in culture medium
and stimulated for 6 hours with PMA (10 ng/ml) and ionomycin
(500 ng/ml) or left untreated. Supernatants were collected; residual
cells and debris were discarded by centrifugation and concentrated
with Concentricon devices (Millipore, Temecula, CA) with a 5-kDa
membrane pore cutoff. A sequential step of PBS dilution and concen-
tration was performed to remove residual PMA and ionomycin that
we found to be toxic for endothelial cells (data not shown).
We evaluated the ability of NK-secreted factors to induce chemo-
taxis of endothelial cells in Boyden chamber assays [25,26] using 5 ×
104 human umbilical vein endothelial cells (HUVECs; Promocell,
Heidelberg, Germany), 12-μm pore size polycarbonate filters pre-
coated with collagen (50 μg/ml), and NK supernatants derived from
mitogen-stimulated or unstimulated purified NK cells. After 6 hours
of incubation, the filters were recovered, and the cells migrated to
the lower filter surface stained with 4',6-diamidino-2-phenylindole
(DAPI; Sigma-Aldrich) and counted in a double-blind manner in eight
consecutive fields per filter with a fluorescence microscope (Zeiss,
Oberkochen, Germany).
The capacity to induce formation of capillary-like networks by
endothelial cells seeded on matrigel (BD) was performed as previously
described [27]. HUVECs (5 × 104 cells/well) were resuspended in
1 ml of tumor infiltrating stimulated or unstimulated NK cell super-
natants obtained as above and transferred to the matrigel-coated
wells for 6- or 24-hour incubation on matrigel, and the morphologic
organization was documented with an inverted microscope (Zeiss).
TGFβ1 Polarization and Angiogenic Cytokine Production
by NK Cells
We evaluated cytokine production (VEGF, PlGF, IL-8, and IFN-γ)
after TGFβ1 stimulation on peripheral blood NK cells isolated frombuffy coats of healthy donors by negative selection NK cell enrichment
as above. Total NK cells were cultured in RPMI 1640 (1 × 106/ml)
supplemented with FBS, IL-2 (100 U/ml), Stem Cell Factor (20 ng/
ml; Miltenyi Biotec), and TGFβ1 at 2, 5, or 10 ng/ml (Miltenyi
Biotec), while the same medium without TGFβ1 was used as control.
The growth factors were added every third day, and after 3 weeks, the
cultures were processed for assessment of surface markers and intra-
cellular cytokine production as described above.
Flow Cytometric and Statistical Analyses
Flow cytometric analyses were performed using BD FACSDiva
(v6.1.2) and FlowJo (v7.2.5) software. Statistical analyses were per-
formed using the GraphPad Prism statistics and graphing program
(GraphPad Software, San Diego, CA). Two-tailed t tests were used
for comparison of paired data sets and quartile localization for popula-
tion distribution.Results
NK Cell Subsets Associated with Angiogenic
Cytokine Production
Previous studies have shown that tumor samples from patients with
NSCLC are enriched in the CD56+CD16− NK subset, which have
been extensively characterized for the expression of specific NKmarkers
displaying a distinct surface molecular pattern [17,18]. Further, the
CD56+CD16− NSCLC infiltrating cells have a limited capacity to de-
granulate and kill tumor cells through an IFN-γ and TNFα-mediated
mechanism [17,18]. As previously observed [17], NK cells represent
2% to 3% of the whole CD45+ leukocytes population within the
tumors, 1.6% on average in adjacent lung tissues, and 7.7% on average
in the peripheral blood (Table 1). The CD56+CD16− NK cell subset
is the major subset in lung tumor samples (Figure 1A), significantly
higher (P < .001) than that in the adjacent lung tissue and peripheral
blood samples and showing higher levels of CD56 expression (Fig-
ure W1). The normal lung tissues obtained from patients that did
not have oncologic disease showed a CD56dimCD16+ profile compara-
ble to that of the adjacent tissues resected along with the NSCLCs
(Figure 1B). We did not observe any significant differences regarding
the prevalence of the CD56+CD16− NK subset between NSCLC
subtypes: the CD56+CD16− NK subset predominated both in AdC
and SCC (Figure 1C), as well as in occasional mixed adenosquamous
or large cell carcinomas (data not shown). Further, we did not observe
any difference in distribution of NK cell phenotype on the basis of
smoking status (Figure 1D). No correlations with tumor grade, stage,
or tumor lymph node metastasis (TNM) statuses were found (data
not shown). Smoking status also did not alter the distribution of the
CD56+CD16− NK subset in control patients as well (data not shown),
indicating that a chronic inflammatory status induced by smoking did
not affect the NK cell phenotype distribution.
The CD56+CD16− subset has been described as a potent producer
of several cytokines following appropriate stimulation [28]. Since
CD56+CD16− dNK cells have been reported to produce angiogenic
factors [9], we evaluated the capacity of the CD56+CD16− subset, pre-
dominantly infiltrating NSCLC, to produce several angiogenic factors,
in particular VEGF, PlGF, and IL-8. Production of IFN-γ, a key
immunomodulatory cytokine endowed with antiangiogenic potential
[29], was also investigated. Following standard PMA and ionomycin
stimulation, the CD56+CD16− NK cell subset was clearly associated
Figure 2. Characterization of tumor infiltrating NK cells by intracellular staining for angiogenic and antiangiogenic cytokines. The
CD3−CD56+CD16− NK cell subset is clearly associated with angiogenic cytokine production, including VEGF, PlGF, and IL-8 in the
tumor and adjacent normal tissues as well as in peripheral blood, where this subset was also associated with enhanced production of IFN-γ.
**P < .01, *P < .05; ns, not significant.
Figure 1. Phenotypic distribution of the CD3−CD56+CD16+ and CD3−CD56+CD16− NK cell subsets as determined by flow cytometry.
(A) NK cell distribution in samples derived from peripheral blood, normal adjacent lung tissues, and tumor tissues of patients with NSCLC.
(B) A similar distribution of NK cell subsets is found in peripheral blood and lung tissues from non-oncologic patients. (C) The tumor in-
filtrating NK cells are primarily of the CD3−CD56+CD16− subset in both AdC and SCC. (D) Smoking status [current, former (Ex), and non-
smokers] did not influence the NK cell subset distribution in tumor or adjacent lung tissues. Significant differences between the CD16+ and
CD16− NK subsets for each group were all P< .0001 except for former smokers in adjacent tissue (P= .0085) and tumors of non-smokers
(insufficient data).
Neoplasia Vol. 15, No. 2, 2013 Proangiogenic Phenotype of NK Cells in Cancer Bruno et al. 137
138 Proangiogenic Phenotype of NK Cells in Cancer Bruno et al. Neoplasia Vol. 15, No. 2, 2013with significantly higher production of the proangiogenic factors
VEGF, PlGF, and IL-8 (Figure 2), in all the compartments examined.
The significantly higher expression of angiogenic cytokines in the
peripheral blood suggests that other innate lymphoid cell subsets, which
can express CD56 but are essentially not found in peripheral blood, are
probably not a confounding factor. Production of IFN-γ after stimula-
tion was lower in adjacent lung tissue and tumor infiltrating NK cells
and higher in the peripheral blood CD56+CD16− NK cells (Figure 2).
Differences in NK Cell Angiogenic Factor Production in
NSCLC Subtypes
We then examined the distribution of cytokines and angiogenic
factors production as a function of tumor subtype and patients’ clinical
parameters. We noted that the VEGF production by CD56+CD16−
NK cells in patients with SCC was significantly higher than in those
with AdC in tumor, adjacent lung tissues, and in particular in periph-
eral blood (Figure 3). CD56+CD16− NK cells from SCC patients also
produced significantly higher levels of PlGF compared to AdC in the
adjacent lung tissues and in peripheral blood compartments, although
there was no difference between the AdC and SCC tumor infiltrating
NK cells (Figure 3).
Given the systemic effect on peripheral blood NK cells in patients
with SCC, we then compared cytokine production with that of periph-
eral blood from 12 healthy donors. The expression of VEGF and PlGF
in the CD56+CD16− NK cells from the peripheral blood of healthy
controls was similar to that of patients with AdC and significantly less
than the CD56+CD16− NK cells from patients with SCC (Figure 3).
Interestingly, we noted that peripheral blood CD56+CD16− NK cellsFigure 3. Differences in angiogenic factor production based on NSC
produce significantly more VEGF than those from patients with AdC. T
This effect appeared to be systemic, as CD3−CD56+CD16− NK cells
VEGF when compared to patients with AdC or to healthy donor con
63%male and 25% smokers (open diamonds,⋄) and four anonymous
from peripheral blood and adjacent tissue from patients with SCC pro
both SCC and AdC showed significantly higher production of IL-8 and
in IL-8 production between NK cells from patients with AdC and SC
compared to AdC. ****P < .0001, ***P < .001, **P < .01, *P < .05;from both AdC and SCC produced high levels of IL-8 that was sig-
nificantly different from that of healthy controls (Figure 3). Expression
of IFN-γ was slightly (albeit significantly) higher in peripheral blood
CD56+CD16− NK cells from AdC compared to healthy controls and
even higher in SCC with significant differences between AdC and
healthy controls (Figure 3). In some SCC patients, more than 50%
of the CD56+CD16− NK cells expressed VEGF, and in the same sam-
ples, more than 50% also expressed IFN-γ. These data suggest that at
least some NK cells from patients with NSCLC can express multiple
cytokines with proangiogenic and antiangiogenic functions. Sample
material was insufficient for comparisons within the tissue compart-
ments for IL-8 and IFN-γ expression.
The correlation between angiogenic cytokine production and histo-
logic and clinical parameters in SCC patients was also examined. In
most of the NSCLC samples, expression of CD56+ was limited to
few cells showing NK characteristics (Figure 4A), with occasional stain-
ing of the tumor epithelial compartment. Most of the CD56+ cells with
an NK phenotype were CD3−, and the distribution of these cells cor-
related with flow cytometric data (Table 1 and Figure W1). CD31
staining showed that all the tumor samples had a highly vascularized
microenvironment (Figure 4B) characteristic of most of the NSCLC
samples. CD57 is not expressed on CD56bright NK cells and is a marker
for a mature, activated phenotype [30]. Interestingly, the SCC pa-
tients showing high angiogenic cytokine production by NK cells were
essentially negative for CD57 staining. A retrospective immunohisto-
chemical study examining CD57+ NK cells found a positive correla-
tion with survival in resected SCC NSCLC [31]. These data further
highlight the role of NK polarization in SCC NSCLC.LC subtype. CD3−CD56+CD16− NK cells from patients with SCC
his was evident both locally in the tumor and in the adjacent tissues.
from patients with SCC showed significantly higher production of
trols [HC, eight donors with a median age of 54; range, 44 to 68;
donors (filled diamonds, ♦)]. In addition, CD3−CD56+CD16− NK cells
duced significantly more PlGF. In the peripheral blood, patients with
IFN-γ compared to healthy controls. While there was no difference
C, those with SCC showed significantly higher production of IFN-γ
ns, not significant.
Figure 4. Immunohistochemistry of SCC. (A) CD56 staining shows
occasional positive cells scattered throughout the tumor. (B) CD31
staining shows extensive tumor vascularization. Bar, 150 μm.
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Promote Angiogenesis-Associated Effects on Endothelial Cells
Given the range of factors produced by NSCLC NK cells, to fur-
ther determine their angiogenic potential, we examined in vitro the
effects of NK cell products on biologic correlates of angiogenesis, in
particular endothelial cell recruitment and morphogenesis.
Supernatants from stimulated NSCLC tumor infiltrating NK cells
were able to induce a significant level HUVEC chemotaxis (Figure 5A)
similar to that of positive controls. Supernatants from unstimulated
cultures showed little chemotactic activity, identical to serum-free
controls. Supernatants from both AdC and SCC tumor-infiltrating
NK cells showed a comparable level of chemotactic activity.
We also examined the ability of NK cell supernatants to promote
capillary-like organization of HUVECs seeded onto matrigel three-
dimensional support (Figure 5, B–D). Supernatants from AdC and
SCC NSCLC infiltrating NK cells, stimulated by PMA and iono-
mycin, induced endothelial cell morphogenesis in vitro following
stimulation (Figure 5C ). Interestingly, in this assay, the unstimulated
NK cells derived from SCC showed a baseline angiogenic activitythat was enhanced following stimulation. Network formation in
the presence of NK cell supernatants from lung tissues and peripheral
blood of control patients without oncologic disease was very limited
(Figure 5D). Taken together, these data suggest that NSCLC infil-
trating NK cells display an enhanced angiogenic potential compared
to non-tumor tissues infiltrating NK cells.
NK Cell Polarization and Cytokine Production after
TGFβ1 Stimulation
TGFβ1 has been shown, at least in vitro, to affect development
and differentiation of human NK cell subsets. TGFβ1 has been re-
ported to convert a fraction of peripheral blood CD56dimCD16+ and
CD56brightCD16+ NK cells into CD56brightCD16− cells that express
killer inhibitory receptors, CD9, and CD103 [23,24], all features of
dNK cells [11]. To our knowledge, however, the capability of in vitro
TGFβ-polarized peripheral blood NK cells to produce proangiogenic
cytokines has not been evaluated. In keeping with previous obser-
vations [23,24], after 7 days of TGFβ1 exposure of healthy donor–
derived NK cells, a significant increase of the CD56brightCD16− subset
(approximately 70% of all NK cells) compared to untreated controls
(approximately 30% of NK cells) was observed (data not shown). More
importantly, exposure of NK cells to TGFβ1 significantly upregulated
the expression of VEGF and PlGF within the CD56+CD16− subset
(Figure 6). The percentages of cells expressing IL-8 or IFN-γ were
quite low and not significantly affected by the TGFβ1 treatment.Discussion
NK cells are lymphocytes of the innate immune system that can
recognize tumor cells as targets and play a key role in antitumor
immunity. Our data demonstrate that, like many other leukocytes,
tumors can polarize these cells to a proangiogenic and protumorigenic
environment, possibly linked to tumor progression. At the moment,
there is very little literature on the capability of NK cells to induce
tumor-sustaining angiogenesis. Given the fact that lung cancer is one
of major causes of cancer-related deaths and that the lung parenchyma
plays a role in tumor progression, we investigated NK cells in NSCLC.
Here, we show that NSCLC tumors induce both local and systemic
polarization of NK cells toward phenotype associated with angiogenesis
and that TGFβ may be one of the mechanisms involved in this pro-
cess. The significantly higher expression of VEGF and PlGF by
CD56+CD16− NK cells in SCC and IL-8 in both SCC and AdC cor-
related with the angiogenic activities found for these cells in functional
assays. NK cells in the peripheral blood of NSCLC patients also ex-
pressed IFN-γ, an antiangiogenic cytokine expressed at high levels by
human, porcine, and murine dNK cells. Studies in mice have indicated
that IFN-γ secretion by dNK cells is involved in positively regulating
decidual vascular lumen size and the spiral artery alterations (see [32]
for review). These data suggest that tumor-polarized NK cells produc-
ing both proangiogenic cytokines and IFN-γ may induce structural
alterations in vessels that might have clinical relevance [33]. The
angiogenic activity of NSCLC “educated” NK cells that also produce
IFN-γ is similar to that of dNK cells and clearly different from the
CD56+CD16− NK cells found in healthy individuals. Further studies
are needed to fully address whether NK cells from NSCLC patients
have other functions and markers of “bona fide” dNK cells or if they
represent a novel NK cell subset.
The presence of an NSCLC, even of modest dimensions, appears to
have a potent systemic effect on the phenotype of the CD56+CD16−
140 Proangiogenic Phenotype of NK Cells in Cancer Bruno et al. Neoplasia Vol. 15, No. 2, 2013NK cells that is more pronounced in SCC. This is in keeping with
transcriptome profiling studies indicating that NSCLC has a distinct
effect on peripheral blood mononuclear cells [34,35], in particular
for SCC. Interestingly, many of the genes making up a prognostic
signature were NK associated [34,35].
VEGF staining has been reported to be an independent prognostic
indicator of poor survival for resectable lung cancer patients [36,37],
particularly for the SCC histotype [38], although this is controversial
[39]. TGFβ has been associated with NK cell dysfunction in melanoma
[40], esophageal SCC [41], and ovarian carcinoma [42]. Changes in
NK receptor profiles in patients with NSCLC [17,18] have been linked
in part to TGFβ [18]. Further, high TGFβ expression by tumor cells
and infiltrating lymphocytes is characteristic of NSCLC and was
found to have a prognostic value for SCC, but not for AdC, for both
compartments [22]. TGFβ-positive tumor-infiltrating lymphocytes
represented the only independent immunologic parameter with prog-
nostic significance after multivariate analysis [22]. TGFβ1 significantly
enhanced expression of VEGF and PlGF from healthy donors, yet did
not enhance expression of IL-8 or IFN-γ, suggesting that other factors
produced by NSCLC tumors or the tumor microenvironment also
influence the NK cell angiogenic phenotype. A potential factor may
be HLA-G, an immunoregulatory class I major histocompatibilityFigure 5. Proangiogenic activity potential of NK cells. (A) Analysis of t
endothelial cell chemotaxis. SFM−, serum-free medium as a negative
with 1% L-glutamine, fibroblast growth factors (10 ng of acidic fibrob
epidermal growth factor (10 ng/ml), heparin (0.1 mg/ml), and hydrocort
supplemented with 10% FBS as a positive control. Supernatants we
unstimulated (NS) or stimulated (S) with PMA and ionomycin. Supe
chemotaxis compared to supernatants from unstimulated NK cells
individually. Media containing only PMA and ionomycin had little che
patients with NSCLC promote endothelial cell capillary-like morphog
above. (C) Supernatants from NK cells isolated from AdCs that were s
induction of endothelial cell morphogenesis compared to supernatan
from SCC showed induction of morphogenesis even when unstimula
these cells harbor a strong angiogenic activity. (D) NK cells isolated from
patients did not show significant enhancement of morphogenesis in thcomplex molecule expressed in the decidua and in many tumors
capable of modulating NK cell function [43,44]. Interestingly, both
tumor and circulating soluble HLA-G have been found to be par-
ticularly high in SCC patients and predictive of poor survival of this
subtype [45,46].
Previous studies have shown that surgically resected samples of SCC
have a significantly shorter (>25% less) tumor doubling times com-
pared to those of surgically resected AdC origin [47], a prognostic fac-
tor [47] that is even more evident using computed tomography scans
that identifies earlier stage tumors [48,49]. However, to date, on the
basis of the TNM system, globally there is no clear-cut difference in
the aggressiveness of these two tumors when size, lymph node infil-
tration, and metastases are considered [50]. A lower overall survival
of SCC compared to AdC NSCLC patients has been reported [51]
possibly attributable to more advanced and invasive cancer status on
resection as well as smoking or age-related comorbidities. The systemic
effect on NK cells shown here and peripheral blood lymphocytes in
general [34,35] may promote comorbidities.
While additional therapeutic options are available for patients with
non-squamous cell subtypes, such as bevacizumab and pemetrexed,
fewer options are available for SCC patients [33], yet are urgently
needed. In addition to suggesting that aberrant activation of NK cellshe capacity of supernatants from NSCLC-derived NK cells to induce
control, containing RPMI 1640 alone. SFM+, serum-free RPMI 1640
last growth factor plus 10 ng of basic fibroblast growth factor/ml),
isone (010 μg/ml). CM, complete medium containing SFM+medium
re isolated from AdC and SCC NK cells cultured for 6 hours either
rnatants from stimulated NK cells showed enhanced induction of
(NS). Similar data were obtained from AdC and SCC supernatants
motactic activity (data not shown). **P < .01. (B–D) NK cells from
enesis, (B) positive (SFM+; CM) and negative (SFM−) controls as
timulated for 6 hours with PMA and ionomycin (stimulated) showed
ts from unstimulated NK cells. Supernatants from NK cells isolated
ted, which was further enhanced upon stimulation, indicating that
the peripheral blood (blood) or lung tissues (lung) of non-oncologic
e presence or absence of stimulation.
Figure 6. Angiogenic phenotype switch induced by TGFβ1 on
healthy donor buffy coat–derived NK cells. After 3 weeks of culture
in 10% FBS, IL-2 (100 U/ml), and SCF (20 ng/ml) either alone (control;
circles,•) orwith TGFβ1 at 2 ng/ml (squares,■), 5 ng/ml (triangles,▲),
or 10 ng/ml (inverted triangles,▼), angiogenic cytokine expression
was measured by flow cytometry. As previously reported [24], after
exposure to TGFβ1, the CD56
+CD16− subset was significantly en-
hanced with respect to the CD56+CD16+ subset compared to con-
trols (data not shown). Exposure to TGFβ1 significantly induced
the expression of the proangiogenic cytokines VEGF and PlGF.
***P < .001; ns, not significant.
Neoplasia Vol. 15, No. 2, 2013 Proangiogenic Phenotype of NK Cells in Cancer Bruno et al. 141in NSCLC may be a therapeutic target, the angiogenic profile of NK
cells might provide a marker for potential responses to, or complications
of, targeted therapies that are currently lacking for SCC of the lung.
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